COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD

9/24 Early, Late
Gasperetti et al., EP Europace, doi:10.1093/europace/euaa216 (Peer Reviewed) (not included in the study count)
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Source   PDF   Share   Tweet
Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.
Arrhythmic safety data from a large cohort of patients treated with HCQ alone or in combination with other QT-prolonging drugs.

Gasperetti et al., 9/24/2020, peer-reviewed, 23 authors.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit